SCHEMBL7414527

SCHEMBL7414527

CC(CCC(=S)NO)NC(=O)c1ccccc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.60
SMN1; SMN2 Q16637 4/20 0.56
KMT2A Q03164 3/20 0.56
MEN1 O00255 2/20 0.56
HTT P42858 1/20 0.56
RAB9A P51151 3/20 0.54
NPC1 O15118 2/20 0.54
HSP90AA1 P07900 1/20 0.53
ALDH1A1 P00352 3/20 0.52
LMNA P02545 2/20 0.50
HDAC1 Q13547 3/20 0.46
HDAC3 O15379 2/20 0.46
HDAC7 Q8WUI4 2/20 0.46
HDAC2 Q92769 2/20 0.46
HDAC8 Q9BY41 2/20 0.46
HDAC6 Q9UBN7 2/20 0.46
HDAC4 P56524 1/20 0.46
HDAC10 Q969S8 1/20 0.46
HDAC11 Q96DB2 1/20 0.46
HDAC9 Q9UKV0 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7417431 0.84 LMNA (0.62) SMN1; SMN2KMT2AMEN1RAB9ANPC1
SCHEMBL8527616 0.83 HPGD (0.69) HPGDSMN1; SMN2KMT2AMEN1HTT
SCHEMBL13753786 0.80 HPGD (0.65) HPGDSMN1; SMN2KMT2AMEN1HTT
SCHEMBL28243627 0.78 HPGD (0.71) HPGDSMN1; SMN2KMT2AMEN1HTT
SCHEMBL1003282 0.78 RAB9A (0.82) HPGDSMN1; SMN2KMT2AMEN1HTT
SCHEMBL28243626 0.78 HPGD (0.71) HPGDSMN1; SMN2KMT2AMEN1HTT
SCHEMBL21141304 0.76 HPGD (0.69) HPGDSMN1; SMN2KMT2AMEN1HTT
SCHEMBL29137460 0.76 RAB9A (0.67) HPGDSMN1; SMN2KMT2AMEN1HTT
SCHEMBL27452233 0.75 RAB9A (0.68) HPGDSMN1; SMN2KMT2AMEN1HTT
SCHEMBL12356355 0.75 RAB9A (0.76) HPGDSMN1; SMN2KMT2AMEN1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6218389-B1 FOR THERAPY AND PROPHYLAXIS OF ARTHRITIS, CANCER, CARDIOVASCULAR DISORDERS; SKIN DISORDERS; OCULAR DISORDERS; INFLAMMATION AND GUM DISEASES, MULTIPLE SCLEROSIS, CACHEXIA, PREVENTING LOOSENING OF PROSTHETIC DEVICES THE PROCTER & GAMBLE CO. 2001-04-17 US disclosed
EP-1009737-A2 SULFONYLAMINO SUBSTITUTED HYDROXAMIC ACID DERIVATIVES AS METALLOPROTEASE INHIBITORS THE PROCTER & GAMBLE COMPANY (US) 2000-06-21 EP disclosed
WO-1999006340-A2 SULFONYLAMINO SUBSTITUTED HYDROXAMIC ACID DERIVATIVES AS METALLOPROTEASE INHIBITORS THE PROCTER & GAMBLE COMPANY (US) 1999-02-11 WO disclosed